Propiedad y actividad de insiders de Coherus Oncology, Inc. (CHRS): operaciones de insiders, transacciones del Senado y la Cámara de EE. UU. y acciones en circulación. Sigue cómo operan la acción los directivos y los políticos.
Precio
| Precio | $1.22 |
| Capitalización | $188M |
| Bolsa | NASDAQ |
| País | US |
Operaciones Recientes de Insiders
| Fecha | Insider | Tipo | Acciones | Valor |
|---|---|---|---|---|
| 2026-06-05 | Satvat Ali J. | A-Award | 60,000 | $87K |
| 2026-06-05 | Satvat Ali J. | A-Award | 30,000 | |
| 2026-06-05 | Karachun Rita A | A-Award | 60,000 | $87K |
| 2026-06-05 | Karachun Rita A | A-Award | 30,000 | |
| 2026-06-05 | Newcomer Lee Nisley | A-Award | 60,000 | $87K |
| 2026-06-05 | Newcomer Lee Nisley | A-Award | 30,000 | |
| 2026-06-05 | Ryan Michael Lee | A-Award | 60,000 | $87K |
| 2026-06-05 | Ryan Michael Lee | A-Award | 30,000 | |
| 2026-06-05 | O'Donnell-Tormey Jill | A-Award | 60,000 | $87K |
| 2026-06-05 | O'Donnell-Tormey Jill | A-Award | 30,000 |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $124.9M | $126.9M | $72.4M | $177.7M | $541.2M | $417.2M | $63.5M | $102.9M | $126.0M | $88.9M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | $128.1M | $14.9M | 0 | $83.2M |
| Cuentas por Cobrar | $1.9M | 0 | 0 | $142.0M | $157.0M | $123.0M | $110.0M | $260.5M | $122.3M | $18.4M |
| Inventario | -$4.8M | 0 | $1.7M | $9.8M | $44.2M | $37.6M | $38.8M | $62.6M | $70.1M | $3.2M |
| Activos Corrientes | $124.9M | $126.9M | $72.4M | $343.0M | $767.5M | $602.3M | $381.2M | $475.6M | $341.6M | $206.7M |
| Inmovilizado Material | $10.8M | $12.8M | $6.7M | $16.5M | $10.1M | $7.8M | $8.8M | $5.1M | $2.8M | $1.3M |
| Fondo de Comercio | $943000 | $943000 | $943000 | $943000 | $943000 | $943000 | $943000 | $943000 | 0 | 0 |
| Activos Intangibles | $2.6M | $2.6M | $2.6M | $2.6M | $2.6M | $2.6M | $5.0M | $70.7M | $53.6M | $46.2M |
| Activos Totales | $178.5M | $162.6M | $99.5M | $408.9M | $841.6M | $679.3M | $480.8M | $629.6M | $448.5M | $258.3M |
| Cuentas por Pagar | $20.6M | $15.7M | $15.3M | $26.0M | $15.2M | $16.2M | $11.5M | $35.2M | $28.5M | $9.9M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $56.4M | $28.4M | $33.3M | $115.0M | $145.7M | $165.3M | $138.7M | $331.8M | $283.0M | $141.9M |
| Deuda a Largo | $100.3M | $101.6M | $103.1M | $178.4M | $404.0M | $408.3M | $471.1M | $473.4M | $264.9M | $37.1M |
| Pasivos Totales | $159.1M | $132.1M | $138.1M | $303.7M | $560.7M | $581.6M | $618.3M | $823.0M | $580.5M | $197.3M |
| Reservas | -$537.3M | -$775.5M | -$984.8M | -$895.0M | -$762.8M | -$1.05B | -$1.34B | -$1.58B | -$1.55B | -$1.38B |
| Patrimonio Neto | $19.4M | $30.5M | -$38.6M | $105.2M | $281.0M | $97.7M | -$137.4M | -$193.4M | -$132.0M | $61.0M |
| Deuda Total | $100.3M | $101.4M | $103.1M | $188.6M | $417.1M | $419.0M | $480.4M | $480.8M | $269.9M | $40.3M |
| Deuda Neta | -$24.7M | -$25.5M | $30.7M | $11.0M | -$124.1M | $1.8M | $288.7M | $363.1M | $143.9M | -$131.8M |
| Capital Circulante | $68.6M | $98.5M | $39.1M | $228.0M | $621.8M | $437.0M | $242.5M | $143.9M | $58.6M | $64.8M |
Salud financiera
| Deuda / Patrimonio | 0.62 |
| Ratio corriente | 1.77 |
Rentabilidad
| Rentabilidad sobre capital | -181.73% |
| Rentabilidad sobre capital invertido | -135.38% |
| Rentabilidad sobre activos | -68.50% |
| Margen bruto | 63.55% |
| Margen operativo | -307.43% |
| Margen neto | -257.10% |
Empresas relacionadas: AVTX · CCCC · CDXS · IMDX · IVVD · OABI · PLX
Explorar sector: Healthcare · Biotechnology
Más secciones de CHRS: Resumen · Financieros · Valoración · Estadísticas · Estimaciones · Técnico · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones